文献速递肝肾功能剂量调整药物相互作用治疗药物监测与药物基因组学

肌酐与N1-甲基烟酰胺的肾脏转运体介导药物-生物标志物相互作用的PBPK建模

Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N1 -Methylnicotinamide: A PBPK Modeling Approach.
PubMed 文献 · Clin Pharmacol Ther · 2022-06-07

本研究开发了内源性OCT2和MATE1底物肌酐与N1-甲基烟酰胺(NMN)的全身PBPK模型,并耦合已建立的甲氧苄啶、乙胺嘧啶和西咪替丁 perpetrator 模型预测药物-生物标志物相互作用。模型准确描述了两种标志物的血浆浓度-时间曲线和尿排泄,并成功预测了合用药物时肌酐血浆浓度升高和尿排泄减少。研究还假设甲氧苄啶和乙胺嘧啶额外抑制NMN合成,改善了NMN预测。

要点

  • 肌酐和NMN的PBPK模型能准确描述其动力学,可支持肾转运体介导DDI研究。
  • 甲氧苄啶、乙胺嘧啶和西咪替丁可升高肌酐血浆浓度并减少其尿排泄。
  • 甲氧苄啶和乙胺嘧啶可能额外抑制NMN合成,需进一步验证。

核心结论

  • 肌酐和NMN的全身PBPK模型能准确描述和预测其血浆浓度-时间曲线及尿排泄。
  • 模型耦合甲氧苄啶、乙胺嘧啶和西咪替丁后,能良好描述药物-生物标志物相互作用中肌酐血浆浓度升高和尿排泄减少。
  • 假设甲氧苄啶和乙胺嘧啶额外抑制NMN合成可改善NMN血浆和尿液相互作用的预测。

研究设计与样本

  • 研究利用外源性给予肌酐或NMN以及内源性合成的研究数据,开发了肌酐和NMN的全身PBPK模型。
  • 模型随后与先前建立并评估的甲氧苄啶、乙胺嘧啶和西咪替丁 perpetrator 模型耦合进行相互作用预测。

主要发现

  • 新开发的模型准确描述和预测了肌酐和NMN观察到的血浆浓度-时间曲线和尿排泄。
  • 在与甲氧苄啶、乙胺嘧啶和西咪替丁的药物-生物标志物相互作用期间,肌酐血浆浓度升高和尿排泄减少被良好描述。
  • 假设甲氧苄啶和乙胺嘧啶额外抑制NMN合成,改善了NMN血浆和尿液相互作用的预测。

临床怎么用

  • 该PBPK模型可支持药物开发过程中肾转运体介导的药物-药物相互作用研究。
  • 模型有助于更好评估肌酐和NMN的动力学,并揭示未来研究的知识空白。

局限性

  • 原文未明确报告模型的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endogenous biomarkers for transporter-mediated drug-drug interaction (DDI) predictions represent a promising approach to facilitate and improve conventional DDI investigations in clinical studies. This approach requires high sensitivity and specificity of biomarkers for the targets of interest (e.g., transport proteins), as well as rigorous characterization of their kinetics, which can be accomplished utilizing physiologically-based pharmacokinetic (PBPK) modeling. Therefore, the objective of this study was to develop PBPK models of the endogenous organic cation transporter (OCT)2 and multidrug and toxin extrusion protein (MATE)1 substrates creatinine and N1 -methylnicotinamide (NMN). Additionally, this study aimed to predict kinetic changes of the biomarkers during administration of the OCT2 and MATE1 perpetrator drugs trimethoprim, pyrimethamine, and cimetidine. Whole-body PBPK models of creatinine and NMN were developed utilizing studies investigating creatinine or NMN exogenous administration and endogenous synthesis. The newly developed models accurately describe and predict observed plasma concentration-time profiles and urinary excretion of both biomarkers. Subsequently, models were coupled to the previously built and evaluated perpetrator models of trimethoprim, pyrimethamine, and cimetidine for interaction predictions. Increased creatinine plasma concentrations and decreased urinary excretion during the drug-biomarker interactions with trimethoprim, pyrimethamine, and cimetidine were well-described. An additional inhibition of NMN synthesis by trimethoprim and pyrimethamine was hypothesized, improving NMN plasma and urine interaction predictions. To summarize, whole-body PBPK models of creatinine and NMN were built and evaluated to better assess creatinine and NMN kinetics while uncovering knowledge gaps for future research. The models can support investigations of renal transporter-mediated DDIs during drug development.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Türk D, Müller F, Fromm MF, et al. Renal Transporter-Mediated Drug-Biomarker Interactions of the Endogenous Substrates Creatinine and N1 -Methylnicotinamide: A PBPK Modeling Approach. Clin Pharmacol Ther. 2022. PMID: 35527512. doi:10.1002/cpt.2636

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。